Accelerate Diagnostics, Inc. (AXDX) Stock Analysis & Investment Frameworks

Accelerate Diagnostics, Inc. (AXDX) stock analysis on Invetso. Review Accelerate Diagnostics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.

Accelerate Diagnostics, Inc. Company Overview

Accelerate Diagnostics, Inc. Key Financial Metrics

About Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc. is an in vitro diagnostics company specializing in solutions for the rapid diagnosis of critical infections, with operations spanning the United States, Europe, and the Middle East. The company's primary offering is the Accelerate Pheno system, an advanced in vitro diagnostic platform. Paired with its dedicated test kit, the Accelerate PhenoTest, this system facilitates quick identification and antimicrobial susceptibility testing (AST) for pathogens responsible for severe or healthcare-associated infections, encompassing both Gram-positive and Gram-negative organisms. The PhenoTest is specifically designed to yield crucial ID and AST results for patients suspected of bacteremia or fungemia – life-threatening conditions marked by high morbidity and mortality risks. Established in 1982, the company initially operated as Accelr8 Technology Corporation before adopting its current name, Accelerate Diagnostics, Inc., in December 2012. Its corporate headquarters are located in Tucson, Arizona.

Accelerate Diagnostics, Inc. Investment Frameworks

Invetso analyzes Accelerate Diagnostics, Inc. (AXDX) across the following frameworks:

Explore More AXDX Research